283 related articles for article (PubMed ID: 32735150)
21. Clinical implications of pharmacogenetic variation on the effects of statins.
Maggo SD; Kennedy MA; Clark DW
Drug Saf; 2011 Jan; 34(1):1-19. PubMed ID: 21142270
[TBL] [Abstract][Full Text] [Related]
22. Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease.
Hoffmann MM
Curr Cardiol Rep; 2018 May; 20(7):56. PubMed ID: 29802474
[TBL] [Abstract][Full Text] [Related]
23. A clinician's guide to statin drug-drug interactions.
Kellick KA; Bottorff M; Toth PP; The National Lipid Association's Safety Task Force
J Clin Lipidol; 2014; 8(3 Suppl):S30-46. PubMed ID: 24793440
[TBL] [Abstract][Full Text] [Related]
24. Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study
.
Maeda A; Ando H; Ura T; Komori A; Hasegawa A; Taniguchi H; Kadowaki S; Muro K; Tajika M; Kobara M; Matsuzaki M; Hashimoto N; Maeda M; Kojima Y; Aoki M; Kondo E; Mizutani A; Fujimura A
Int J Clin Pharmacol Ther; 2017 May; 55(5):409-415. PubMed ID: 28157071
[TBL] [Abstract][Full Text] [Related]
25. An update on efflux and uptake transporters as determinants of statin response.
Rocha KCE; Pereira BMV; Rodrigues AC
Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):613-624. PubMed ID: 29842801
[TBL] [Abstract][Full Text] [Related]
26. Genetic determinants of response to statins.
Peters BJ; Klungel OH; de Boer A; Maitland-van der Zee AH
Expert Rev Cardiovasc Ther; 2009 Aug; 7(8):977-83. PubMed ID: 19673675
[TBL] [Abstract][Full Text] [Related]
27. [Genetic marker of statin-induced rhabdomyolysis].
Chiba K; Morimoto K
Yakugaku Zasshi; 2011 Feb; 131(2):247-53. PubMed ID: 21297370
[TBL] [Abstract][Full Text] [Related]
28. Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
Licito A; Marotta G; Battaglia M; Benincasa G; Mentone L; Grillo MR; De Lucia V; Leonardi G; Bignucolo A; Comello F; Di Francia R; De Lucia D
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):469-477. PubMed ID: 31957862
[TBL] [Abstract][Full Text] [Related]
29. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
Lee N; Maeda K; Fukizawa S; Ieiri I; Tomaru A; Akao H; Takeda K; Iwadare M; Niwa O; Masauji T; Yamane N; Kajinami K; Kusuhara H; Sugiyama Y
Drug Metab Pharmacokinet; 2019 Dec; 34(6):387-395. PubMed ID: 31594719
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics of statins therapy.
Puccetti L; Acampa M; Auteri A
Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):228-36. PubMed ID: 18221122
[TBL] [Abstract][Full Text] [Related]
31. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
[TBL] [Abstract][Full Text] [Related]
32. Gene-gene-environment interactions between drugs, transporters, receptors, and metabolizing enzymes: Statins, SLCO1B1, and CYP3A4 as an example.
Sadee W
J Pharm Sci; 2013 Sep; 102(9):2924-9. PubMed ID: 23436703
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.
Kim TE; Shin D; Gu N; Jung BH; Kim J; Cho YM; Yu KS; Cho JY
Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):195-201. PubMed ID: 28627804
[TBL] [Abstract][Full Text] [Related]
34. [Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy].
Rumyantsev NA; Kukes VG; Kazakov RE; Rumyantsev AA; Sychev DA
Ter Arkh; 2017; 89(1):82-87. PubMed ID: 28252633
[TBL] [Abstract][Full Text] [Related]
35. Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review.
Vassy JL; Chun S; Advani S; Ludin SA; Smith JG; Alligood EC
Clin Pharmacol Ther; 2019 Aug; 106(2):360-373. PubMed ID: 30137643
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetic study of statin therapy and cholesterol reduction.
Marian AJ
Curr Atheroscler Rep; 2005 May; 7(3):177-8. PubMed ID: 15811249
[No Abstract] [Full Text] [Related]
37. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population.
Kadam P; Ashavaid TF; Ponde CK; Rajani RM
J Clin Pharm Ther; 2016 Jun; 41(3):329-33. PubMed ID: 26932749
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
Dong OM; Wheeler SB; Cruden G; Lee CR; Voora D; Dusetzina SB; Wiltshire T
Value Health; 2020 Jan; 23(1):61-73. PubMed ID: 31952675
[TBL] [Abstract][Full Text] [Related]
39. Pragmatic Trials in Genomic Medicine: The Integrating Pharmacogenetics In Clinical Care (I-PICC) Study.
Brunette CA; Miller SJ; Majahalme N; Hau C; MacMullen L; Advani S; Ludin SA; Zimolzak AJ; Vassy JL
Clin Transl Sci; 2020 Mar; 13(2):381-390. PubMed ID: 31808996
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts.
Dagli-Hernandez C; Zhou Y; Lauschke VM; Genvigir FDV; Hirata TDC; Hirata MH; Hirata RDC
Pharmacol Rep; 2022 Feb; 74(1):47-66. PubMed ID: 34403130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
